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Abstract
Background Experts estimate that the prevalence of antibiotics use
exceeds the prevalence of bacterial acute respiratory infections
(ARIs).
Objective To develop, adapt and validate DECISION+ and esti-
mate its impact on the decision of family physicians (FPs) and their
patients on whether to use antibiotics for ARIs.
Design Two-arm parallelclusteredpilotrandomizedcontrolledtrial.
Setting and participants Four family medicine groups were ran-
domized to immediate DECISION+ participation (the experimen-
tal group) or delayed DECISION+ participation (the control
group). Thirty-three FPs and 459 patients participated.
Intervention DECISION+ isamultiple-component,continuingpro-
fessional development program in shared decision making that
addresses the use of antibiotics for ARIs.
Main outcome measures Throughout the pilot trial, DECISION+
was adapted in response to participant feedback. After the consul-
tation, patients and FPs independently self-reported the decision
(immediate use, delayed use, or no use of antibiotics) and its quality.
Agreement between their decisional conﬂict was assessed. Two weeks
later, patients assessed their decisional regret and health status.
Results Compared to the control group, the experimental group
reduced its immediate use of antibiotics (49 vs. 33% absolute
diﬀerence = 16%; P = 0.08). Decisional conﬂict agreement was
stronger in the experimental group (absolute diﬀerence of Pearsons
r = 0.26; P = 0.06). Decisional regret and perceptions of the quality
of the decision and of health status in the two groups were similar.
doi: 10.1111/j.1369-7625.2010.00616.x
96   2010 Blackwell Publishing Ltd Health Expectations, 14 (Suppl. 1), pp.96–110Discussion and conclusions DECISION+ was developed success-
fully and appears to reduce the use of antibiotics for ARIs without
aﬀecting patients outcomes. A larger trial is needed to conﬁrm this
observation.
Introduction
The use of antibiotics for acute respiratory
infections (ARIs) has contributed to the antibio-
tics resistance that presently plagues Canadians.
1
ARIs are the most frequently reported motive
for primary care consultations in North Amer-
ica.
2 While ARIs have many forms, a large
proportion is viral: only 38% of acute rhino-
sinusitis cases in adults, 5–15% of acute phar-
yngitis cases in adults, and 6–18% of ARI cases
in children are bacterial.
3,4 Nonetheless, experts
estimate that antibiotics are used for between 63
and 67% cases of ARI
5–7. This suggests that
antibiotics are overused.
8,9
Attempts to optimize the use of antibiotics for
ARIs in ambulatory settings have proven less
eﬀective than anticipated.
10 Various aspects of
the provider–patient interaction have been
studied. The physicians perception of the
patients (or the parents) expectations or resis-
tance to a diagnosis of viral infection is one of
the strongest predictors of a physicians decision
to prescribe antibiotics.
11–15 In patients, a good
understanding of the nature of their illness (i.e.,
that the ARI is viral) is associated with their
satisfaction with the consultation.
16 This sug-
gests that the beliefs, concerns and expectations
of both physicians and patients should be taken
into consideration when developing interven-
tions to reduce the inappropriate use of anti-
biotics for the treatment of ARIs. Typically,
however, interventions have been provider-
oriented: little attention has been paid to patient-
based interventions and even less to interventions
combining physicians, patients and public
education.
A promising solution can be found in shared
decision making (SDM), a process in which a
healthcare decision is made by both the clinician
and the patient together.
17,18 SDM aims to help
patients play an active role in decisions con-
cerning their health, the ultimate goal of patient-
centered care.
19 SDM rests on the best evidence
of the risks and beneﬁts of all the available
options.
17 Thus, the clinicians ability to com-
municate with the patient in such a way as to
enable him ⁄her to weigh the risks and beneﬁts of
various treatment choices is essential.
20 Indeed,
SDM takes place in a context in which the
patients values and preferences are sought out
and his ⁄her opinions valued without excluding
the values, preferences and opinions of the cli-
nician.
21 It is a partnership in which the
responsibilities and rights of each party are
articulated, the beneﬁts to each are clear, and the
uncertainty associated with the best choice is
made explicit (clinical equipoise).
22 SDM holds
that mutual acceptance [of a treatment
option]… remains a necessary prerequisite to
agreement between the patient and the provider
on a plan of action.
23 Moreover, SDM has been
shown to lower the overuse of screening or
treatment options not clearly associated with
health beneﬁts for all.
24
Conceptual framework
In our published protocol,
25 we argue that
teaching family physicians (FPs) about the
probabilistic aspect of a diagnosis (in this case, a
diagnosis of bacterial versus viral ARI); pre-
senting them with the best evidence of the ben-
eﬁts and the risks associated with the clinical
options (e.g., prescribing or not prescribing
antibiotics); and giving them strategies to
communicate with patients and involve them
in decision-making, leads to SDM during the
clinical encounter (Fig. 1). This SDM would
optimize FPs and patients decisions regarding
screening or therapeutic options such as antibio-
tics. Optimal decisions by FPs would translate
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by patients would lead to their optimal use of
treatment (e.g., taking antibiotics for their ARI
if appropriate). In addition, patients would not
regret their decision. Ultimately, population
health would improve and quality of life would
ameliorate. Consequently, one of our main
outcomes of interest was the level of agreement
between the patients decisional conﬂict score
and the decisional conﬂict score of his ⁄her FP.
Although, in this pilot trial, decisional conﬂict
was not one of our main outcomes of interest, its
assessment in patients may be valuable. A
Cochrane systematic review of 55 studies indi-
cates that patient decision aids known to
increase patients involvement in decision-mak-
ing are associated with reduced decisional con-
ﬂict in patients.
26 This suggests that increasing
patients involvement in the decision-making
process may help lower their decisional conﬂict.
This ﬁnding is congruent with a meta-analysis of
10 studies indicating that decisional conﬂict is
strongly associated with patients decisional
delay and decisional regret.
27 In turn, decisional
regret correlates with overall quality of life
ratings.
28
Notwithstanding its potential for optimizing
decisions in clinical practice, SDM is not yet
widely adopted and tests of its eﬀectiveness are
needed.
29 For this reason, we conducted a pilot
trial in the clinical context of ARI, whose aims
were (1) to assess the feasibility of recruiting
family medicine groups (FMGs), FPs and their
patients; (2) to develop, adapt and validate
DECISION+ training workshops and related
material (for a description of DECISION+, see
Intervention); (3) to evaluate physicians par-
ticipation and satisfaction regarding DECI-
SION+; and (4) to estimate the impact of
DECISION+ on (i) physicians and patients
decision whether to use antibiotics, (ii) physi-
cians and patients decisional conﬂict scores
and the level of agreement between those
scores, (iii) the prescription proﬁle of antibiotics
for ARIs, (iv) FPs intention to practice SDM,
(v) FPs intention to follow clinical practice
guidelines for the treatment of ARIs, (vi) FPs
scores on a script concordance test, and
(vii) patients decisional regret.
25 This paper
covers aims 2 and 4. Aims 1 and 3 are discussed
elsewhere.
30
Materials and methods
Trial design and population
Between November 2007 and March 2008, we
conducted a pilot, two-arm parallel clustered
randomized clinical trial (RCT) whose main
objective was to assess the feasibility of a larger
clustered RCT. Details of the trial protocol are
reported elsewhere.
25 Brieﬂy, FMGs from the
Quebec City, Canada, greater urban area were
invited to participate. An FMG is a group of
FPs who work closely with nurses to oﬀer family
medicine services to registered individuals.
Participating FMGs were randomized either to
an experimental group that was immediately
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98exposed to the DECISION+ program or to a
control group for which the introduction of
DECISION+ program was delayed for
6 months (Fig. 2).
A biostatistician simultaneously randomized
all FMGs and allocated them to groups using
Internet-based software. FPs were the main
target population and were recruited through
FMGs. The trials investigators and research
assistants and participating FPs were not
blinded to the group allocation. However, codes
were attributed to the trial groups and the bio-
statistician analysed the data blindly. Team
members accessed the codes only after having
completed the analyses and interpreting the
results.
Participants and eligibility criteria
Family practitioners were eligible to participate
if they had not previously participated in an
implementation trial of SDM and if they
planned to remain in clinical practice for the
duration of the trial. Patients were eligible to
participate if they were consulting their FP for
an ARI. No age restrictions were imposed.
Patients (or their guardians) had to be able to
read, understand, and write French and had to
give informed consent to participate in the trial.
Patients with a condition requiring emergency
care were excluded.
Development, adaptation and validation of the
intervention (DECISION+)
Designed on the basis of previous exploratory
work,
29,31–33 DECISION+ is a theory-based,
continuing professional development program
made up of three main components: (i) interac-
tive workshops and related material; (ii) remin-
ders of expected behaviours; and (iii) feedback
to FPs on the agreement between their deci-
sional conﬂict and that of their patients.
25
A series of three interactive workshops was
developed with local opinion leaders and experts
in medical education from the two continuing
medical education oﬃces involved in this trial.
34
A 1.5-h training workshop introducing FPs to
Family medicine groups (FMGs)  
n = 24
Randomization 
n =4
- Did not meet inclusion criteria  
   (n = 3) 
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Patient recruitment (5 Pt/FP)  Patient recruitment (5 Pt/FP) 
DECISION + 
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FOLLOW-UP 
FP dropout
Promoted (n = 1) 
Analysis 
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Figure 2 Trial ﬂow diagram.
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32 was expanded to include all components
of the conceptual framework underlying this
pilot trial
25 and to comply with continuing
professional development regulations that stated
that workshops must last at least 3 h for FPs to
be reimbursed for their attendance. The result-
ing three 3-h interactive workshops addressed (i)
the probability that primary care physicians
would encounter bacterial versus viral ARIs
(rhinosinusitis, bronchitis, pharyngitis, and otitis
media); (ii) scientiﬁc evidence of the beneﬁt ⁄risk
balance of the various treatment options; (iii)
risk communication techniques; and (iv) strate-
gies for fostering patient participation in the
decision-making process.
25 Each workshop was
piloted and modiﬁed in response to participants
feedback, and each workshop was attended by
four to six people: Family practitioners and
residents in family medicine from the research
teams academic network and medical education
experts. Each pilot workshop was audiotaped
and participants completed an evaluation form.
A research assistant acted as a non-participant
observer. After each workshop, the research
team debriefed the session with the participants
and among themselves in order to address any
problems. In the end, four, rather than three,
pilot workshops were conducted because the
second workshop was completely redesigned
and repiloted after feedback on its ﬁrst testing
was received.
Overall, participants found that the pilot
workshops were well structured and well docu-
mented. They felt that both the workshops and
the tools were relevant and potentially useful
enough to be implemented in clinical practice.
However, they suggested that more time be
spent on practical and less on theoretical
aspects.
All workshops included videos of simulated
patient–FP consultations for each ARI. These
videos were produced speciﬁcally for this train-
ing program and distinguished two approaches:
usual care or SDM. First, clinical vignettes
depicting usual care were developed with the
help of experienced clinicians. The research
team then adapted the vignettes to depict a
SDM consultation based on our conceptual
framework. Each workshop included exercises
to facilitate group discussion about facilitators
and barriers to SDM in this context. The
research team developed ﬁve decision support
tools: one for each of the four targeted ARIs
(rhinosinusitis, pharyngitis, bronchitis and acute
otitis media) and one integrating all four ARIs.
Each tool was designed to help FPs understand
and communicate to their patients the probabi-
listic nature of the diagnosis of a bacterial ARI
as well as the risks and beneﬁts of using or not
using antibiotics. During each workshop, FPs
received decision support tools and through
video examples and group exercises were trained
to use them. These tools were provided pro-
gressively: one per workshop, one between two
workshops, and one after the third workshop.
This schedule allowed FPs to experiment with
the tools between workshops and provide feed-
back to the research team during the next
workshop. Using this feedback, the research
team improved the tools iteratively (e.g., by
rounding the number of patients whom physi-
cians should treat from 7 to 10, to make it easier
for physicians to remember).
The research team also produced educational
material for the participants (a booklet sum-
marizing the content of the workshop, clinical
tools) and training manuals for the co-trainers.
Co-trainers were recruited among the FPs who
had participated in the pilot workshops. They
were expected to co-lead the workshops when
the principal investigators could not do so. For
this trial, all workshops were conducted at each
FMG and all were led by the two principal
investigators or by co-trainers.
The second component of DECISION+
consisted of two types of reminders. The ﬁrst
type were diﬀerent reminders, each of which was
printed on one letter-size sheet of paper, that
emphasized the use of the decision support tools
discussed in the previous workshop and reiter-
ated the expected SDM-related behaviours.
They also highlighted new studies relevant to the
pilot trial topics (e.g., new evidence on the risks
and beneﬁts of antibiotics). These reminders
were mailed to FPs between each workshop. The
second type were postcards that participants
SDM and avoiding excessive antibiotic use, F Le ´gare ´ et al.
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workshop in order to remind themselves of what
they needed to implement in their practice. The
research team collected the postcards and mailed
them 6–8 weeks later.
The third component of DECISION+ con-
sisted of the research team informing FPs of the
level of agreement between their score on the
decisional conﬂict scale (DCS) with the scores of
the ﬁrst ﬁve of their patients recruited in the
trial. During the last workshop, FPs were given
a personal letter in a sealed envelope. This letter
speciﬁed the level of agreement between each
FPs decisional conﬂict scores and those of
his ⁄her ﬁrst ﬁve patients. Family practitioners
were not informed of their or their patients
decisional conﬂict scores per se. However, family
practitioners were informed of the performance
of their colleagues in the group, for comparison
purposes. The research team explained how to
interpret the scores. DECISION+ was con-
ducted over a 4–6 months period. Apart from
completing data collection forms at their entry
into the study, FPs in the control group were not
involved in any particular intervention prior to
their delayed exposure to DECISION+.
Recruitment
The research team generated a random list of all
FMGs in the Quebec City area. Based on that
list and in sequence, one of the principal inves-
tigators (FL or ML) telephoned each physician
in charge of an FMG to seek a meeting with
him ⁄her and his ⁄her FMG colleagues to explain
the nature of the project. FPs were either
recruited at that meeting or by a research pro-
fessional who individually met eligible FPs.
Participating FPs were not involved in recruiting
patients. Rather, a research professional waited
in the FMGs waiting room and, with the per-
mission of medical and nursing staﬀ, recruited
patients of enrolled FPs during walk-in clinic
hours. Posters about the project were displayed
in the waiting room and the medical receptionist
handed small promotional cards to patients
when the patients checked in. Patients interested
in participating in the trial met with the research
assistant, who veriﬁed their eligibility to partic-
ipate. Fifteen patients were recruited per FP: ﬁve
at baseline (T0), ﬁve after the FPs in the exper-
imental group were exposed to DECISION+
(T1), and ﬁve after the FPs in the control group
were exposed to DECISION+ (T2). All partic-
ipants (i.e., both FPs and patients) signed an
informed consent form approved by the Ethics
Committee of the Saint-Franc ¸ ois dAssise
Hospital of the Quebec University Hospi-
tal Center. Participants were not ﬁnancially
compensated.
Outcome measures and collection procedures
Sociodemographic information was recorded at
trial entry for FPs and before the consultation
for patients. After the consultation, at T0,T 1
and T2, both the patient and the FP indepen-
dently completed a self-administered question-
naire that assessed the decision about using
antibiotics (immediate use, delayed use, or no
use) and the respondents perception of the
quality of the decision (a single item on a
10-point Likert scale). The participants also
completed the DCS.
35 The questionnaire also
measured patients intention to engage in SDM
in future consultations concerning antibiotics
for ARIs. Family practitioners intentions to
engage in SDM and comply with clinical prac-
tice guidelines regarding prescribing antibiotics
for ARIs were assessed T0,T 1 and T2. All
intentions were assessed with a three-item, seven-
point Likert scale, and questionnaires were based
on the Theory of Planned Behaviour.
36 Two
weeks after the consultation, patients were con-
tacted by phone to complete the Decision Regret
Scale
28 and report their perceptions of health
changes since the consultation.
Data on the number of prescriptions ﬁlled by
patients covered by Quebecs public drug insur-
ance plan were extracted from the Re ´ gie de
lAssurance-Maladie du Que ´ bec medication
claims database during the 3 months preceding
T0 and during the 3 months after FPs in the
experimental group were exposed to DECI-
SION+ (T1). A script concordance test was
developed with the help of experts in ARIs, in
SDM and avoiding excessive antibiotic use, F Le ´gare ´ et al.
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37 This test probes
whether respondents knowledge is eﬃciently
organized to take appropriate clinical action. It
places respondents in written, but authentic,
clinical situations in which they must interpret
data to make decisions. More speciﬁcally, it
measures the concordance between respondents
scripts and the scripts of a panel of experts. The
script concordance test was administered to FPs
at each data collection point. Outcome measures
and collection procedures were similar for par-
ticipating FPs from both the experimental and
control groups.
Statistical analyses
The data from all randomly allocated units (the
FMGs) were analysed on an intention-to-treat
basis, regardless of the FPs adherence to the
intervention. Because this was a pilot trial, we
did not calculate sample size. Missing data on
completed questionnaires averaged 8 ± 8%
(range 0–19%). To construct a complete dataset,
we imputed a random value for all missing data
using the maximum likelihood estimation
method.
38 For each outcome, we calculated the
diﬀerence between groups at T1 and the relevant
95% conﬁdence interval. In addition, we
assessed the statistical signiﬁcance of diﬀerences
between groups using multilevel modeling
(Generalized Linear Mixed Models), accounting
for the hierarchical structure of the data by
specifying random eﬀects at each level
(FMG ⁄FP ⁄patient). The potential confounding
eﬀect of the baseline characteristics of FPs and
patients on the association between the exposi-
tion to DECISION+ and the decision to use
antibiotics (immediate use versus delayed use or
no use) was also assessed using multilevel mod-
eling. We considered an adjusted P-value of
<0.05 as statistically signiﬁcant. As the agree-
ment between FPs and patients answers was
very high (Kappa = 0.90; P < 0.001), we
report only patients answers regarding the
decision to use antibiotics.
To evaluate the sustainability of the pro-
grams eﬀect, we calculated the diﬀerence
between the results at T2 and those at T1 for
each outcome in the experimental group. Rep-
licability of the programs eﬀect was evaluated
by ﬁrst calculating the diﬀerence between T2 and
T0 results for each outcome in each trial group
and then calculating the diﬀerence between trial
groups. A diﬀerence tending towards 0 indicates
the sustainability (T2 –T 1 in the experimental
group) or the replicability [(T0 –T 2 in the
experimental group) ) (T0 –T 2 in the control
group)] of the eﬀect of DECISION+. As these
were exploratory analyses, 95% conﬁdence
intervals were only performed to assess the
precision of our estimates of diﬀerences. All
statistical analyses were performed using the
SAS statistical package (SAS Institute Inc. 2005.
SAS OnlineDoc
  9.1.3; SAS Institute Inc., Cary,
NC, USA).
Results
Participants
Figure 2 depicts the ﬂow of the RCT. Four of
the 21 eligible FMGs were enrolled and ran-
domized either to the experimental group
(FMGs = 2, FPs = 18, patients = 245) or to
the control group (FMGs = 2, FPs = 15,
patients = 214). A ﬁfth FMG agreed to partic-
ipate but notiﬁed us too late to be randomized.
After discussion, we suggested that this FMG be
exposed to DECISION+ at the same time as
the delayed-exposure FMGs (the control group).
Because the ﬁfth FMG had not been random-
ized, however, its data were not considered for
this paper but are reported elsewhere.
30
Characteristics of FMG and FPs are pre-
sented in Table 1 and patient information is
presented in Table 2. Otherwise, FP and patient
characteristics were comparable between trial
groups and no characteristic emerged as a con-
founding factor of the association between the
intervention and the use of antibiotics.
Although Quebecs public prescription drug
insurance plan covers 41% of the provincial
population, it only covered antibiotics pre-
scriptions for 123 (27%) of the 459 patients
recruited for our study. The proportion of
FMGs FPs who chose to participate in the trial
SDM and avoiding excessive antibiotic use, F Le ´gare ´ et al.
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than in the control group (68%). Out of the 33
enrolled FPs, only three FPs (9%) dropped out
of the trial; 20 patients (8%) from the experi-
mental group and 14 patients (5%) from the
control group could not be contacted over the
2-week follow-up.
Outcome measures at T1
Table 3 presents the results at baseline (T0) and
after the DECISION + program was imple-
mented in the experimental group (T1). None of
the diﬀerences between the experimental and the
control groups at T1 were statistically signiﬁ-
cant. However, the magnitude of the diﬀerence
between the groups on some outcomes none-
theless suggests that the program had a positive
eﬀect. While the groups were similar at baseline
(T0), the experimental group had, at follow-up
(T1), reduced its immediate use of antibiotics by
16% compared to the control group. This
reduction is highly clinically signiﬁcant. The
intracluster correlation coeﬃcient calculated on
the decision about using antibiotics as reported
by the patient was 0.02 (patients nested within
an FP). The reduction in the mean proportion of
patients covered by Quebecs public drug insur-
ance plan who ﬁlled a prescription for an anti-
biotic was 6%.
The correlation coeﬃcient for DCS scores
among FPs and patients in the experimental
group, although low, was higher than in the
control group. This indicates better agreement
on the decisional process between FPs and
patients in the experimental group. The inten-
tions of FPs to engage in SDM in future con-
sultations regarding the use of antibiotics for
ARIs increased in both groups, with higher
intentions in the experimental group. Most
patients considered their health to be either
stable or improved 2 weeks after the consul-
tation, with a slightly higher proportion of
patients in the experimental group having a
positive perception of their health status. There
was no diﬀerence between trial groups insofar as
the following elements were concerned: FPs and
patients decisional conﬂict scores and percep-
tions of the quality of the decision, FPs inten-
tions to comply with clinical practice guidelines
regarding the use of antibiotics for ARIs,
patients intentions to engage in SDM in future
consultations regarding the use of antibiotics for
ARIs, and patients decisional regret.
Table 1 Characteristics of participating FMGs and family physicians, by study group
Characteristics Experimental group Control group
Family Medicine Groups FMG 1 FMG 2 FMG 3 FMG 4
Number of physicians 10 10 12 10
Number of female physicians 74 7 5
Number of walk-in hours per weekday 12 8 12 8
Approximate number of patients seen per day 70 50 110 50
Participating family physicians n ⁄N (%) 18 ⁄20 (90) 15 ⁄22 (68)
Women n ⁄N (%) 10 ⁄18 (56) 9 ⁄15 (60)
Mean ± SD years of age 48 ± 94 8 ± 7
Mean ± SD years of professional experience 22 ± 92 1 ± 10
Mean ± SD number of working hours per week 45 ± 11 43 ± 14
Mean ± SD number of patients seen per week 105 ± 47 105 ± 29
Preferred role in decision making n ⁄N (%)
Patient decides 4 ⁄18 (22) 0 ⁄15 (0)
Patient decides, considering physicians opinion 4 ⁄18 (22) 8 ⁄15 (53)
Both parties decide 3 ⁄18 (17) 1 ⁄15 (7)
Physician decides, considering patients opinion 6 ⁄18 (33) 6 ⁄15 (40)
Physician decides 1 ⁄18 (6) 0 ⁄15 (0)
FMG, family medicine group; SD, standard deviation.
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Table 4 presents the outcome measures of both
trial groups after the control group was exposed
to DECISION+ (T2). The proportion of
patients in the experimental group who decided
to use antibiotics immediately after the consul-
tation was similar at T2 and T1 (35 vs. 33%;
absolute diﬀerence 2%). Results for all other
outcomes were also similar at T2 and T1 for this
group.
By comparing the diﬀerences between T2 and
T0 results in the experimental and control
groups, we explored the eﬀect of the program
once the intervention was replicated. In the
experimental group, 21% fewer patients decided
to use antibiotics immediately at T2 (35%) than
at T0 (56%). In the control group, the reduction
was only 8% between T2 (54%) and T0 (46%).
This 13% diﬀerence indicates that insofar as
this outcome is concerned, the DECISION+
program had less eﬀect in the control group
than in the experimental group. Comparable
results were observed for all other variables,
with the exception of FPs intentions to engage
in SDM in future consultations regarding anti-
biotics for ARIs: these intentions improved
similarly in the two groups. Unanticipated
technical diﬃculties with the script concordance
test precluded its use as an outcome measure.
Experts could not achieve consensus on the
expected answers.
Table 2 Patient characteristics by study group and data collection period
Patient characteristics
Experimental group Control group
Total population
n = 459
T0
n = 92
T1
n = 81
T2
n = 72
T0
n = 77
T1
n = 70
T2
n = 67
Number of women (%) 62 (67) 57 (70) 50 (69) 57 (75) 47 (68) 51 (76) 324 (71)
Number of adults (%) 55 (60) 54 (67) 57 (79) 61 (79) 46 (66) 48 (72) 321 (70)
Mean ± SD years of age 37 ± 12 36 ± 13 40 ± 13 41 ± 13 38 ± 12 37 ± 11 40 ± 14
Number of children (%) 37 (40) 27 (33) 15 (21) 16 (21) 24 (34) 19 (28) 138 (30)
Mean ± SD years of age 4 ± 35 ± 43 ± 37 ± 55 ± 45 ± 45 ± 4
Number of participants
whose family
income ‡ Cdn.
$45 000 ⁄year (%)
51 (55) 43 (56) 41 (62) 38 (54) 42 (63) 44 (72) 259 (60)
Number of participants
currently working (%)
63 (68) 58 (72) 57 (70) 61 (80) 57 (83) 58 (87) 354 (77)
Number of participants with
a university or college
degree (%)
51 (55) 57 (72) 44 (61) 44 (58) 39 (57) 41 (63) 271 (60)
Number of participants with
public drug insurance (%)
27 (29) 32 (40) 18 (25) 17 (22) 21 (30) 8 (12) 123 (27)
Preferred role in decision making, n (%)
Patient decides 4 (4) 4 (5) 5 (7) 3 (4) 5 (7) 2 (3) 23 (5)
Patient decides,
considering physicians
opinion
29 (32) 35 (43) 23 (32) 24 (33) 25 (36) 17 (26) 153 (34)
Both parties decide 31 (34) 16 (20) 21 (29) 14 (19) 16 (23) 12 (18) 110 (24)
Physician decides,
considering patients
opinion
16 (17) 19 (23) 14 (19) 24 (33) 13 (19) 21 (32) 107 (24)
Physician decides 12 (13) 7 (9) 9 (13) 8 (11) 11 (16) 13 (20) 60 (13)
Because of missing values, the denominator for some characteristics differ from the sample size.
Cdn, Canadian; SD, standard deviation; T0, baseline; T1, after DECISION+ was implemented in the experimental group; T2, after DECISION+ was
implemented in the control group.
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104In light of these results and using proposed
guidelines for reporting complex behaviour
change interventions,
39 we explored the inter-
vention context and process and noted diﬀer-
ences. Among FP participating in the trial, the
proportion of those who attended the three
workshops was similar in both groups (experi-
mental = 9 ⁄18, 50% vs. control group = 7 ⁄15,
47%). However, we found that not all work-
shops had been conducted by the same individ-
uals. In the experimental group, ﬁve of the six
workshops (three per FMG) had been con-
ducted by both principal investigators (FL and
ML), whereas only one of the six workshops in
the control group were lead by them.
Discussion
In this trial, we successfully developed, adapted
and validated DECISION+, a theory-based,
continuing professional development program.
This program comprised three main compo-
nents: (i) interactive workshops and related
material; (ii) reminders of expected behaviours;
and (iii) feedback to FPs on the agreement
between their decisional conﬂict and that of their
patients. Our results suggest that DECISION+
reduces FPs and patients decision to use anti-
biotics and increases the level of agreement
between their decisional conﬂict scores without
aﬀecting decisional regret and patients self-
reported health improvements at 2 weeks. We
also observed that the eﬀect of DECISION+
lasted at least until after the control group was
exposed to the program (a period of about
8 months). These results provide valuable
information regarding three aspects of the future
RCT.
The ﬁrst concerns the development, adapta-
tion and validation of DECISION+. Although
our results suggest that the intervention is sus-
tainable over 8 months, we could not reproduce
Table 3 Outcome measures at baseline (T0) and after the implementation of the DECISION+ program in the experimental group
(T1), by study group
Outcome
Experimental group Control group
Difference
at T1 (95% CI) P-value* T0 T1 T0 T1
Patients who decided to use antibiotics
immediately (%)
56 33 54 49 )16 ()31 to 1) 0.08
Mean proportion of patients who ﬁlled a
prescription (%)
79 45 70 51 )6 ()17 to 6) 0.35
Correlation of FPs and patients DCS
scores (Pearsons r)
0.14 0.24 )0.05 0.02 0.26 ()0.06 to 0.53) 0.06
Mean ± SD score of the quality of the decision
FPs 8.8 ± 1.18 .7 ± 1.28 .3 ± 1.48 .5 ± 1.30 .2 ()0.34 to 0.89) 0.29
Patients 8.2 ± 2.18 .7 ± 1.98 .4 ± 1.98 .6 ± 1.90 .1 ()0.88 to 0.94) 0.57
Mean ± sd score of the intention§
FPs to engage in SDM 0.8 ± 0.81 .3 ± 1.20 .3 ± 1.60 .8 ± 1.30 .5 ()0.2 to1.3) 0.77
FPs to comply with CPGs 1.9 ± 0.82 .1 ± 0.91 .8 ± 0.82 .2 ± 0.5 )0.1 ()0.7 to 0.5) 0.58
Patients to engage in SDM 1.1 ± 1.40 .7 ± 1.40 .8 ± 1.60 .8 ± 1.4 )0.1 ()0.6 to 0.4) 0.16
Patients with decisional regret (%) 17 19 )2 ()12 to 5) 0.91
Patients who felt they had stable, a little better,
or much better health at 2 weeks (%)–
87 94 91 85 9 ()2 to 18) 0.08
CI, conﬁdence interval; CPGs, clinical practice guidelines; DCS, decisional conﬂict scale; FP, family physician; SD, standard deviation; SDM, shared
decision-making, T0, baseline; T1, after DECISION+ was implemented in the experimental group.
*All P values except the difference between correlations were adjusted for baseline values (T0) and the studys cluster design.
Among patients covered by Quebecs public drug insurance plan who consulted a participating physician for an acute respiratory infection (as
reported for billing purposes).
1 = very low quality to 10 = very high quality.
§)3 = strongly disagree to +3 = strongly agree.
–Versus not much worse or much worse.
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105in the control group the results observed in the
experimental group. When workshops were not
conducted by the principal investigators (ML
and FL), they failed to produce the expected
change. In addition to the principal investi-
gators obvious motivation to have the program
succeed, it is possible that either both or one of
the principal investigators involved in the
training sessions may have been acting as a local
opinion leader, that is, an individual perceived
by his or her colleagues as likeable, trustworthy,
and inﬂuential; someone who acts as a persua-
sive agent of behavioural change.
40 Our ﬁndings
of the importance of carefully choosing, training
and motivating the workshop leaders have
therefore caused us to modify our procedure for
the future trial. We plan four new strategies:
videoconferencing workshops so that the same
pair of trainers can train participants at several
sites at the same time; fewer trainers; a stan-
dardized train-the-trainers workshop; and
assessment of the trainers before they are
allowed to conduct training.
The second aspect of the future trial
informed by our results regards outcomes
assessment. Based on the estimate and conﬁ-
dence intervals of patients immediate decision
to use antibiotics (our main outcome) and its
related intracluster correlation coeﬃcient, we
calculate that with six clusters (FMGs), we will
need 360 patients at each data collection point
to detect a reduction from 60 to 40% with 80%
power and a 5% signiﬁcance.
41 Given the small
proportion of participating patients who were
covered by Quebecs provincial drug plan (27%
compared to 41% of the provincial population),
Table 4 Outcome measures in the study groups after the DECISION+ program was implemented in the control group (T2);
assessment of the sustainability and replicability of the effect of the program
Outcomes
Experimental
group at T2
Control
group at
T2
Difference
in the experimental
group between
T1 and T2 (95% CI)*
Difference between the
change in the experimental
group between T0 and T2
and the change in the
control group between
T0 and T2 (95% CI)*
Patients who decided to use antibiotics
immediately (%)
35 46 2 ()14 to 16) )13 ()39 to 6)
Correlation of FPs and patients DCS scores
(Pearsons r)
0.17 0.18 )0.1 ()0.4 to 0.2) )0.1 (CI cannot
be estimated)
Mean ± SD score of the quality of the decision
FPs 8.7 ± 1.18 .5 ± 1.00 ()0.4 to 0.2) )0.3()0.8 to 0.1)
Patients 9.1 ± 2.18 .1 ± 1.80 .4 ()0.2 to 1.1) 1.2 (0.3–2.3)
Mean ± sd score of the intention
FPs to engage in SDM 1.4 ± 0.70 .7 ± 1.00 .1 ()0.5 to 0.7) 0.05 ()0.9 to 1)
FPs to comply with CPGs 2.1 ± 0.72 .0 ± 0.90 ()0.5 to 0.5) 0 ()0.6 to 0.7)
Patients to engage in SDM 1.1 ± 1.50 .7 ± 1.30 .4 ()0.1 to 0.8) 0.1 ()0.5 to 0.7)
Patients with decisional regret (%) 39 )4 ()22 to 7) )6 ()30 to 22)
Patients who felt they had stable, a
little better, or much better health
at 2 weeks§ (%)
94 91 0 ()8 to 8) 7 ()6 to 21)
CI, conﬁdence interval; CPGs, clinical practice guidelines; DCS, decisional conﬂict scale; FP, family physician; SD, standard deviation; SDM, shared
decision making; T0, baseline; T1, after DECISION+ was implemented in the experimental group; T2, after DECISION+ was implemented in the
control group.
*A difference tending towards 0 indicates the sustainability (T2 –T 1 in the experimental group) or the replicability [(T2 –T 0 in the experimental
group) ) (T2 –T 0 in the control group)] of the DECISION+ program.
1 = very low quality to 10 = very high quality.
)3 = strongly disagree to +3 = strongly agree.
§Versus a little worse or much worse.
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106we will not collect provincial drug registry
information in the future trial. Instead, we will
copy the prescription received by participating
patients immediately after the consultation.
Finally, because of the diﬃculties associated
with developing and scoring the script concor-
dance test, we will not use this test in the larger
trial.
Although not statistically signiﬁcant and
originating from a pilot project, our results are
somewhat congruent with those of two recently
published RCTs.
42,43 These two studies showed
that FPs trained in communication skills and
patient-centered care prescribed less antibiotics
than did FPs without such training, and that
prescription rates and absolute use dropped
within the ranges observed in our trial. Our
observations are also congruent with the con-
clusions of a Cochrane review on the eﬀective-
ness of interventions to improve the use of
antibiotics for ARIs in ambulatory settings.
44
Patient-mediated interventions and physician
reminders were found to be potentially eﬀective
methods deserving further study.
44 Finally,
although DECISION+ trained physicians in
SDM and gave them tools to conduct SDM with
their patients, we realized that it would be
important that the next trial assess patients
exposure to these tools. Consequently, we have
devised a strategy to expose patients to the tools
and measure their exposure.
In addition to assessing FPs intention to use
SDM in practice, we evaluated the potential
eﬀect of DECISION+ on FPs intention to use
clinical practice guidelines. Physicians some-
times perceive the pressure to apply clinical
practice guidelines as a barrier to SDM.
45
Although decision-makers, researchers, patients
organizations and other stakeholders are placing
increasing emphasis on the need to incorporate
patients perspectives and SDM within clinical
practice guidelines,
46 little, if anything, is known
about combining the implementation of a SDM
approach with the implementation of clinical
practice guidelines. Our results suggest that it is
possible to implement SDM in FPs practices
without damaging FPs intentions to comply
with clinical practice guidelines.
Nevertheless, our pilot RCT has limitations.
With respect to the development, adaptation
and validation of DECISION+, we only
assessed participants exposure to and appreci-
ation of the workshops. We did not assess their
exposure to the other two components of
DECISION+. It was often diﬃcult to distin-
guish between the full DECISION+ program
(all components) and the series of three work-
shops (one component). Also, we could not
assess the replicability of DECISION+. As
discussed above, we plan to reduce the number
of co-trainers and modify their training. With
respect to the outcomes assessment, we
acknowledge that the DCS alone may not be an
adequate outcome measure of the quality of the
decisional process regarding the use of antibi-
otics for ARIs in primary care. Decisional con-
ﬂict scores were very low in both FPs and
patients at T0 and remained so at T1 and T2.
However, one of our main outcomes of interest
was the agreement between the DCS score of the
patient and the score of his ⁄her FP. Although at
T1, FPs and patients DCS scores correlated
more closely in the experimental group than in
the control group (suggesting stronger agree-
ment among experimental group participants
regarding comfort with the decision), the clinical
signiﬁcance of the magnitude of the diﬀerence
(0.26) is questionable.
Notwithstanding these limitations, we suc-
cessfully developed, adapted and validated
DECISION+, a multi-component, continuing
professional development program in SDM that
addresses the use of antibiotics for ARIs. Some
of the lessons learned in this pilot trial may be
relevant to training FPs in SDM for other clin-
ical contexts and decisions. Our pilot trial –
particularly its intervention and its methods –
was based on a conceptual framework that is
generic enough to be adapted to other contexts.
The exploratory assessment of the programs
impact suggests that DECISION+ has the
potential to reduce the proportion of FPs and
patients deciding to use antibiotics immediately
for ARIs. Nonetheless, a large clustered RCT
will be necessary to more accurately evaluate the
impact of DECISION+ on the decision to use
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107antibiotics for ARIs and to assess the programs
sustainability.
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